Skip To Main Content
Darbi Witmer on Muck Rack

Darbi Witmer

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Darbi

Contact Darbi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

IL-2 mutein-engrafted antibody MHS552 selectively expands functional regulatory T cells in nonclinical models and healthy participants

|
By Igor Radanovic, Michael DiDonato, Anouk C. Meijs, David Schubert, Andrea Kiessling, Hannah Morgan, Justin McMullen, Thomas P. Buters, Pim Gal, Susanne Osanto, Morten Bagger, Claudio Calonder, Ulrike Sommer, Frank Waldron-Lynch, Peter Gergely, Esther Kamphausen, Céline Rauld, Camille Regairaz, Timothy D. Tree, Naomi B. Klarenbeek, Matthijs Moerland, Robert Rissmann, Glen Spraggon, Leona Gabryšová, Yaiza Diaz-de-Durana, Thierry Flandre, Claudia Simonett, Manon AA. Jansen, Sjoerd H. van der Burg, Darbi Witmer, Nadege Pelletier, Nicole Hartmann, Magdalena Kistowska, Helene Marsot, Anita Auger-Sarrazin, Yann Ladner
| Nature Verified
Abstract Low-dose interleukin-2 (IL-2) shows potential for treating autoimmune disorders by expanding regulatory T cells (Treg), but therapeutic utility is limited by short half-life and off-target effects. Here, we describe the molecular design, nonclinical development, and first-in-human study of MHS552, an IL-2 mutein-engrafted antibody designed to selectively expand Treg via high-affinity IL-2 receptors.
Open in Who Shared Issue with article?
See all 1 articles